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Abstract
Our objective was to characterize the saccadic eye movements in patients with type 3 Gaucher disease (chronic
neuronopathic) in relationship to neurological and neurophysiological abnormalities. For approximately 4 years, we
prospectively followed a cohort of 15 patients with Gaucher type 3, ages 8–28 years, by measuring saccadic eye movements
using the scleral search coil method. We found that patients with type 3 Gaucher disease had a significantly higher
regression slope of duration vs amplitude and peak duration vs amplitude compared to healthy controls for both horizontal
and vertical saccades. Saccadic latency was significantly increased for horizontal saccades only. Downward saccades were
more affected than upward saccades. Saccade abnormalities increased over time in some patients reflecting the slowly
progressive nature of the disease. Phase plane plots showed individually characteristic patterns of abnormal saccade
trajectories. Oculo-manual dexterity scores on the Purdue Pegboard test were low in virtually all patients, even in those with
normal cognitive function. Vertical saccade peak duration vs amplitude slope significantly correlated with IQ and with the
performance on the Purdue Pegboard but not with the brainstem and somatosensory evoked potentials. We conclude that,
in patients with Gaucher disease type 3, saccadic eye movements and oculo-manual dexterity are representative
neurological functions for longitudinal studies and can probably be used as endpoints for therapeutic clinical trials.
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Introduction
Gaucher disease is an autosomal recessive disorder that results
from the deficiency of the lysosomal enzyme glucocerebrosidase
and the accumulation of glucosylceramide in macrophages
systemically in most patients [1]. The chronic neuronopathic
form of Gaucher disease (type 3 Gaucher disease, GD3), is a
neurological disorder that has a very variable clinical expression. It
is associated with an accumulation of glucosylceramide in
perivascular macrophages and in brain glial cells and in neurons
[2,3]. Recent studies in mice models for neuronopathic Gaucher
disease confirmed that GD3 is primarily a neuronal disorder with
an important additional role of astrocytes, while lipid laden
macrophages (Gaucher cells) play a minor modulator role [4].
The hallmarkclinical abnormality ofpatients with neuronopathic
Gaucherdisease consists ofmarkedly slowhorizontal saccades [3,5].
The term saccade initiation failure or oculomotor apraxia has been
used for this neurological deficit [6]. However, we and others have
observed for some time that vertical saccades are slow as well but to
a lesser extent and this deficit lags in time [6,7,8].
There is currently no effective specific treatment for the
neurological aspects of Gaucher disease. High dose enzyme replace-
ment therapy has an effect on the visceral disease, but unfortunately
it has no effect on the brain [9]. For the development of future
therapies it is important to longitudinally document the natural
history as quantitatively as possible. We recently reported the
progression of saccadic and other neurological and neuropsycho-
logical abnormalities over two years as part of a treatment trial [7].
The course of the neurological disease progression in that study was
slow, therefore, it is of particular interest to further quantitate and
better characterize the neurological course of GD3 over a longer
period of time. Vertical saccadic function was chosen as a primary
outcome measure because vertical saccades were abnormal in all
our subjects but were much less affected than horizontal saccades.
In some of our subjects horizontal saccades were so abnormal as to
be unrecordable. Thus vertical saccade performance was felt to be a
more likely parametric measure than horizontal saccades which had
a floor effect. In addition to the characterization of the eye
movements we investigated how the vertical saccade abnormality
correlates with systemic and neurological parameters in GD3. The
determination of the eye-hand coordination and oculo-manual
dexterity especially was a special function of interest, because of its
role in everyday life activities. Saccadic eye movements are an
important component of coordination [10]. Abnormal eye-hand
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disturbed in a variety of other neurological conditions, such as
cerebral palsy, occulomotor apraxia, Parkinson’s disease, and aging
[10,11,12,13,14]. Patients with GD3 were also found to demon-
strate abnormal cortical inhibition compared to controls as
determined by somatosensory evoked potentials [15]. Progressive
abnormalities in brainstem auditory evoked responses in patients
withGaucherdiseaseweredescribed[16].Thesefindingscorrelated
with an absence of neurons in the cochlear nuclei and a hypoplastic
superior olivary complex [17]. Long-term longitudinal data of both
markers have not been available yet and therefore are of particular
interest.
In order to fully characterize the saccadic abnormalities in
Gaucher disease, we prospectively studied the saccadic character-
istics in 15 patients with GD3, with an emphasis on vertical
saccades, using a reliable recording method for eye movements.
To better understand the progression of the disease and the
relevance of the saccadic abnormality in GD3, we also evaluated
its relationship to other important brain functions and pathways.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Figure 1. CONSORT diagram for this study.
doi:10.1371/journal.pone.0022410.g001
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Ethics Statement. All patients or their legal guardians gave
their written informed consents. This paper consists of a
description of 15 patients with Type 3 Gaucher disease (Figure 1)
who were prospectively followed at the Clinical Center of the
National Institutes of Health on an approved clinical research
protocol of the National Institute of Neurological Disorders and
Stroke, NIH (ClinicalTrials.gov identifier: NCT00001289). The
criteria for inclusion in this report were patients who were studied
on more than one visit using the scleral search coil method for
assessing saccadic eye movements (see below).
The patients were 8 males and 7 females with a mean age of
15.765.4 (age range 8 to 28). For eye movement studies, patients
were followed for a mean of 2.361.0 years. A normal control
group was composed of 10 subjects: 5 males and 5 females with a
mean age of 16.7 years (age range 11 to 31).
Eye Movements
Patients had a general ophthalmologic assessment before
assessment of saccadic eye movements, to identify visual
impairment. Horizontal and vertical saccadic eye movements
were recorded using a scleral search coil technique and were
sampled at 1 kHz using Realtime (EXperimentation) (REX) [18].
The subjects sat with their head in a chin cup and their forehead
against a headrest and faced a screen 1 meter away on which a red
laser spot was back projected (the spot subtended about 0.5 deg). A
mirror galvanometer moved the target spot in a pseudorandom
sequence from -15 deg to +15 deg with target jumps of 2.5, 5, 7.5,
10, 12.5, 15, 20, 25, 30 deg in each direction. The target jumped
approximately every 3 seconds with about 0.5 sec variability.
Subjects were instructed to follow the target with their eyes. A
minimum of 100 target jumps was recorded for a sequence of
vertical saccades and then a minimum of 100 target jumps for
horizontal saccades. The eye position data was then filtered and
differentiated to obtain eye velocity. Saccades were detected using
a velocity criterion, and their characteristics (latency, amplitude,
duration, and peak velocity) were determined (Figure 2). Saccade
latency is defined as the time from target onset to the time of eye
motion onset using velocity criteria (Figure 2). Saccade gain is
defined as the amplitude of the first saccade made to a target
divided by the target’s distance from fixation (Figure 2). Saccade
peak duration is defined as saccade amplitude divided by saccade
peak velocity and was used to linearize the graph of saccade
velocity vs amplitude, often referred to as the main sequence
[18,19,20]. The graph of saccade duration vs amplitude tended to
be linear and further manipulations were not necessary [18,20].
Regression lines were fitted to the data of saccade peak duration vs
amplitude and saccade duration vs amplitude as a method to
summarize saccade performance for any particular recording
session. Slower, more abnormal saccades yielded regression slopes
that were larger for duration vs amplitude graphs and larger for
peak duration vs amplitude graphs.
Methods of evaluating systemic disease
Skeletal abnormalities were assessed using plain films of the long
bones. Hematological parameters as well as pulmonary status,
spine, liver and spleen volume were assessed as previously
described [21].
Methods of evaluating neurological disease
Neuropsychological assessments included Purdue Pegboard test
and Wechsler scale administered as part of a larger battery of
neuropsychological tests that included measures of attention and
memory. Only the results of the Wechsler IQ scales and the Purdue
Pegboard test are presented here. The Wechsler scales are widely
used, standardized IQ tests. The Purdue Pegboard test is a validated
test of manual dexterity and eye-hand coordination. It consists of a
board, approximately 30.5 cm645.5 cm, with two parallel rows of
25 holes each. Pegs are located at the top of the board in wells, one
to the left and one to the right. Between the peg wells are two
additional wells containing washers and collars. In the first of 4
trials, the subject removes one peg from the well on the same side as
the dominant (observed writing) hand and places the peg in the first
holeon the same side. A short practice is required, and then the trial
is timed for 30 seconds. In the second of the 4 trials, the procedure is
repeated with the nondominant hand. In the third trial the subject
removes a peg from each well simultaneously and places the pegs in
the holes on the respective side of the board. In the fourth and last
trial, the subject takes a peg with the dominant hand, while
simultaneously taking a washer with the nondominant hand and
placing the peg in the top hole on the dominant hand side, slipping
the washer onto the peg. With the dominant hand a collar is
retrieved, placed on the washer while a second washer is retrieved
with the nondominant hand and placed atop the collar. This
completes one assembly. The subject is given 60 seconds to make as
many4-partassembliesaspossible.Numberofcorrectlyplacedpegs
(for trials 1 through 3) and number of pieces correctly assembled are
compared to published norms and expressed in z-scores [22,23].
Standard EEG, brainstem auditory evoked response (BAER),
somatosensory evoked potentials (SSEP) using median nerve
stimulation and stretch-evoked methods, as previously described,
were performed on each subject at each visit to the NIH. In the
stretch-evoked SSEP, the muscle stretch was produced by tapping
the subject’s hand with a plastic hammer [15]. Absolute and inter-
peak latency values were obtained from the BAER, and P1-N2
amplitude data were obtained from the SSEP. BAER and EEG
Figure 2. Saccadic eye movement parameters.
doi:10.1371/journal.pone.0022410.g002
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(higher numbers indicating greater abnormality).
Statistical methods
Correlation analyses using Spearman’s rank correlation coeffi-
cient were conducted between the slopes of peak duration vs
amplitude for vertical saccades of patients and each of the
neuropsychological parameters and systemic parameters, respec-
tively, with a two-tailed significance level of 0.05. Similarly,
correlation analyses for horizontal saccade regression slope and
vertical saccade regression slope were done respectively.
To control for the effect of age at saccadic testing, Spearman’s
partial rank correlation coefficient was used to explore correlation
between any pair of BAER or SSEP and vertical or horizontal
slope.
To explore the time effect on each of the neurological, non-
neurological or systemic parameters except for BAER score and
SSEP amplitude, multivariate analysis of variance (MANOVA)
models with time as a within factor were used. Time effect on
BAER score or SSEP amplitude was examined using a
multivariate analysis of covariance (MANCOVA) with time as a
within factor and age at saccadic testing as a covariate. The
covariance structure was assumed to be first order auto regressive
covariance structure while using the Kenward-Roger degrees of
freedom method in both MANOVA and MANCOVA.
Analyses were implemented in SAS PROC Corr and PROC
Mixed (SAS Institute Inc., Cary, North Carolina: Littell et al.
1996) with a=0.05.
Results
Patient characteristics
The 15 patients were followed over 2–4 years with repeated
testing. General patient characteristics are described in Table S1.
Eleven of the patients were homozygotes for the common L444P
mutation and together with patient 5 they presented with typical
stable chronic neuronopathic clinical abnormalities with underly-
ing severe systemic disease (Table S2). Patient 2 had progressive
myoclonic encephalopathy with seizures. All patients except one
were on enzyme replacement therapy (ERT) with imiglucerase for
years, while patient 14 was successfully treated with hematopoietic
stem cell transplantation. Ten patients temporarily received
investigative substrate reduction therapy (OGT 918, miglustat)
as part of a clinical trial [7].
Saccadic eye movements abnormalities
In examining the saccades of patients we focused particularly on
the relationship between peak duration (defined as peak velocity/
amplitude) and amplitude using the slope which was calculated by
linear regression fit of the saccades [19].
All patients in this current study had abnormal saccadic
velocities with vertical saccades less affected than horizontal
saccades. In 9 of 15 patients, the downward saccades were slower
than upward ones. Comparing the slopes of amplitude vs duration
for downward vs upward saccades for the patients, downward
saccades were significantly longer in each patient (9.1565.72 vs
5.2162.02 with p,0.01) and more variable. Slopes of peak
duration vs amplitude of downward saccades were also signifi-
cantly greater than upward saccades (4.6763.66 vs 2.5561.04
with p,0.04) and this was noted in 13 of 15 patients.
The latency of horizontal saccades was longer than vertical
saccades in patients and significantly slower than the vertical
saccades of normal controls (Table 1). However, the latency of
vertical saccades of patients was only slightly longer than normal.
The gain of horizontal saccades was lower than vertical in patients
and gains for both horizontal and vertical saccades were
significantly smaller than in normal controls (Table 1). Studying
the slopes of regression of saccade duration vs amplitude,
horizontal saccades of patients were most affected, followed by
downward saccades and least affected were upward saccades. All
slopes of saccade duration vs amplitude fits were larger than for
healthy controls (Table 1). Comparing the slopes of saccade peak
duration vs amplitude, the same pattern emerged (Table 1).
We asked whether patients with more severely affected
horizontal saccades would have more severely affected vertical
saccade parameters. Graphing the slopes of horizontal vs vertical
saccades for duration vs amplitude and peak-duration vs
amplitude we found correlation coefficients of 0.31 in both cases
(p,0.005, Figure 3A, 3B). The regression of horizontal vs vertical
saccade latency had a correlation coefficient of 0.68 (p,0.005,
Figure 3C). This suggests that the two systems do tend to track
together, both worsening with disease progression. However, the
correlation is imperfect, in part because there is a floor effect when
the horizontal saccades are very poor and cannot become any
worse. For several patients with the longest follow up, we viewed
saccadic parameters across time and were unable to demonstrate a
consistent decline in follow up visits by looking at the slopes of
peak duration vs amplitude for each patient’s upward saccades
over time (Figure 4). Upward saccades were chosen since these
were the least abnormal. Graphing downward and horizontal
saccade slopes over time did not demonstrate any consistent
pattern of decline (see also below).
Table 1. Saccade Characteristics. Comparison of saccade
parameters of patients and normal controls using data from
their last visit.
Saccade Latency Gaucher Normal T test
Right 0.3460.14 0.2060.03 0.004
Left 0.3260.10 0.2060.02 0.002
Up 0.2560.09 0.2160.03 0.24
Down 0.2560.06 0.2360.06 0.52
Saccade Gain Gaucher Normal T test
Right 0.5460.17 0.8960.07 2.5610
26
Left 0.5760.22 0.8960.06 0.0001
Up 0.8260.19 0.8860.10 0.36
Down 0.7360.19 0.9060.06 0.015
Slope of Duration vs
Amplitude Gaucher Normal T test
Right 13.8766.15 2.7160.43 4.9610
26
Left 14.2066.64 2.6660.52 9.1610
26
Up 5.2162.02 3.1660.93 0.006
Down 9.1565.72 3.4160.97 0.005
Slope of Peak Duration
vs Amplitude Gaucher Normal T test
Right 7.6962.45 1.6260.29 3.1610
28
Left 9.3964.63 1.6760.45 1.6610
25
Up 2.5561.04 1.7560.62 0.04
Down 4.6763.65 1.7960.50 0.02
doi:10.1371/journal.pone.0022410.t001
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saccades when viewing phase planes of position vs velocity, and
these unique patterns remained over time. In contrast, phase
planes of the saccades of normal controls tended to resemble each
other (Figure 5).
Other Systemic and Neurological Characteristics
Hematological parameters and organ volumes at each testing
visit as well as whether or not the patient was on OGT 918
(miglustat) are described in Table S2. In a recent randomized
controlled trial, miglustat had no effect on saccadic velocity[7].
Platelet counts and hemoglobin levels were normal or near normal
in all patients. Neuropsychological testing and neurophysiological
testing at each visit (when available) are described in Tables S3
and S4 respectively. IQ ranged from well above average to severe
mental impairment (full scale IQ ranges from 124 to 40).
Remarkably, the performance on the Purdue Pegboard test was
generally abnormal even in patients with normal cognitive
function (Table S3). Only four patients had completely normal
BAER (Table S4). Patients 2 and 4 had elevated SSEP amplitude
both by median nerve stimulation and by stretch reflex (hammer)
as seen in patients with progressive myoclonic encephalopathy of
Gaucher disease. Four patients had partial complex seizures with
or without secondary generalization that was not associated with
elevated SSEP amplitude, suggesting a focal onset that is not part
of a progressive epileptic encephalopathy.
Change Over Time and Correlations
To explore the time effect on each of the neurological and non-
neurological (systemic) parameters we found that only liver volume
had a significant time effect (p,0.01). In order to assess whether
the severity of the saccadic abnormalities reflects the overall
impairment in GD3, we investigated possible correlations between
the severity of the saccadic eye movement deficit and the systemic,
neurophysiologic and neuropsychological parameters (Tables 1
and S3-S4) using Spearman’s rank correlation coefficient. When
looking at the initial record of each patient, significant correlation
was found between Verbal IQ (p,0.02), Performance IQ
(p,0.04), Full-Scale IQ (p,0.02) and the downward saccade
slope. Significant correlation was found between the vertical
saccade peak duration slope and the performance of the patients
on the Purdue Pegboard when the patient used both hands (trial 3)
(p=0.01). There was no significant correlation between the BAER
and SSEP and the saccadic eye movement parameter except for
BAER on the right side (p=0.04).
Discussion
In this paper we describe the various characteristics and the
natural history during a 4-year follow up of the saccadic eye
movement abnormalities in patients with GD3 and their
relationship to other aspects of neurological function.
Horizontal saccadic abnormalities are the hallmark of GD3 and
all our patients also demonstrated both horizontal and vertical
saccadic abnormalities. Optokinetic nystagmus and vestibular
Figure 3. A. Slope of peak duration vs amplitude for vertical vs
horizontal saccades. The line is a least squares regression of the data
points and has an R
2 value of 0.3. This graph suggests there is a
tendency for vertical and horizontal saccade performance to track
together and the p value for that tendency is ,0.005. B. Graph of
regression slopes of saccade duration vs amplitude for vertical vs
horizontal saccades. Again the least squares regression fit of the data
points is shown and has an R
2 value of 0.31. The test for relationship has
ap ,0.005. C. Graph of vertical vs horizontal latencies (data from the
last visit). The regression line has an R
2 of 0.68 and the test for
relationship has p,0.00001.
doi:10.1371/journal.pone.0022410.g003
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[5,6,8].
The pathophysiology underlying the saccade abnormalities in
neuronopathic Gaucher disease is unclear. Several brain areas are
involved with saccade generation including the cerebellum, basal
ganglia and brainstem. The brainstem areas attributed to saccadic
control include the parapontine reticular formation (PPRF) for
horizontal saccades and the midbrain rostral interstitial nucleus of
the medial longitudinal fasciculus (riMLF) for vertical saccades
[10]. Our study showed that although vertical saccade lagged
horizontal saccade abnormalities, both tended to deteriorate
together. We might expect to see less disease involvement in the
riMLF than in the PPRF on autopsy studies. However, in
neuronopathic Gaucher autopsy material the brainstem shows
widespread gliosis and neuronal loss making it hard to distinguish
discrete nuclei in the advanced disease state [2]. It is interesting
that downward saccades were often more affected than upward
saccades and this has also been noted in parkinsonian syndromes
such as progressive supranuclear palsy and other neuro-degener-
ative diseases with vertical saccade abnormalities [24]. This likely
represents differential disease effects on the vertical saccade
generation pathways.
The phase plane plots of Figures 3 and 4 reveal some interesting
aspects of saccade performance in these patients. In comparison to
normal controls who produce a smooth family of curves for
different saccade amplitudes, each patient has a somewhat
idiosyncratic and characteristic family of velocity trajectories,
often with slowing and speeding up of the saccade during its flight,
which appears as wiggles in the curve. These velocity variations
are more often present for larger amplitude saccades and for
patients with more severely affected saccades. This may reflect
problems with turning off cells in the brainstem saccade
omnipause region, which might be interfering with the saccade
progress [10]. Another aspect that can be seen in these patients’
phase plane plots is that there were fewer large amplitude saccades
produced (reflecting decreased gain) and the peak velocity during
any given saccade was smaller. Unlike normal controls whose
phase planes look similar to each other, each patient’s saccade
performance created a fairly unique velocity vs position phase
plane and retained its individuality over time. This might
represent unique patterns of differential degeneration in individ-
uals affecting their saccade generation. Lastly, there was some
suggestion of saccade performance deterioration over the 4 years
time course in the two examples of Figure 3, suggesting disease
progression.
The significant correlation between the most prominent
measurable saccadic abnormalities and other neurological param-
eters (IQ and brainstem auditory function) suggests a correlation
between cerebral disease state (as reflected in IQ) and brainstem
pathology (as reflected in saccade velocity). Therefore, measure-
ment of saccadic eye movements may be an adequate represen-
tation of the neurological deficit in GD3 and may be a useful
biomarker as part of a neuropsychological and neurophysiological
testing battery which should also include IQ measurements in
Figure 4. Slope of peak duration vs amplitude for upward saccades over time. Each point represents the results for a specific visit time.
doi:10.1371/journal.pone.0022410.g004
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the presence of a significant correlation between the biomarker
and the ‘true’ clinical endpoint is necessary to validate surrogate
endpoints in clinical trials [25,26]. The absence of a comprehen-
sive correlation between all the saccadic eye movement parameters
and the systemic, neuropsychological and neurophysiological
characteristics may be due to the small number of subjects along
with the variability of the test results, but it also indicates the
variability of clinical deficits and disease phenotype among our
patients. For example, patients 3 and 12 had normal to high
cognitive function, yet had saccadic deficits that were not unlike
those of patients with cognitive impairment.
Saccadic eye movements have been used as primary clinical
outcome measures in two recent clinical trials [7,27]. They are
useful because of their reproducibility, easy quantification and
because symptomatic patients with Niemann-Pick disease type C
or neuronopathic Gaucher disease have slow saccades, although
patients with Niemann-Pick disease type C mainly have vertical
saccadic initiation failure [27]. Deficits in saccadic eye movements
limit activities such as using a computer, driving, crossing the street
or going up or down stairs. The absence of significant change
overall in saccadic velocity over the follow up period suggests that
in this form of Gaucher disease the pathological process is very
slow. However, there was a clear decline over time in some
patients that was similar to the decline observed in auditory
brainstem responses [16].
Similar to the saccades, the absence of statistically significant
change within the neurophysiological and neuropsychological
endpoints over the observed time was probably caused by a
combination of very slow change, relatively short follow up period
and small sample size.
In this study we also validated the stretch reflex method as a
useful approach for recording SSEP in a more physiological
manner [15]. This method is particularly useful for small children
since it does not involve the unpleasant sensation related to
electrical median nerve stimulation[15].
This study has several limitations. All patients were referred to a
research institution and may not reflect the general population of
patients with GD3. In addition, although we describe the natural
history of the encephalopathy associated with GD3, the patients in
this study are not, strictly spoken, ‘untreated’. However, neither
ERT nor miglustat have demonstrated any clinical benefit on the
neurological outcome in GD3.
The net effect of ERT cannot be assessed since all patients are
put on ERT because it has a marked effect on the non-
neurological aspects of neuronopathic Gaucher disease [21].
Although theoretically possible, it is unlikely that ERT has some
salutary effect on saccades, because it is not believed to cross the
blood-brain barrier. In addition, it is possible that the cells
involved in saccade generation are not simply dysfunctional but
rather have been killed by the Gaucher disease process and in that
case the best we would expect is that treatment would prevent
further progression and the saccade parameters would remain
stable over time. We could not demonstrate that the use of
miglustat had an influence on the progression of the saccadic eye
movement abnormalities, in part because there was not much
change in saccade parameters over the observed period [7].
In addition to slow saccadic eye movements, we found that
virtually all patients with neuronopathic Gaucher disease, even those
with normal cognition and neurologicalexamination, have a deficit in
eye-hand coordination as documented in the Purdue Pegboard test.
In view of the lack of uniform correlation with vertical saccadic eye
movement parameters, this manual dexterity deficit is not caused by
the supranuclear gaze palsy but likely by a cortical/subcortical
dysfunction. This finding suggests involvement of other centers such
as the superior colliculus that is implicated in saccade selection and
gaze anchoring during natural reaching movements critical for
adequate eye-hand coordination [28,29]. Therefore, the almost
uniform Purdue Pegboard abnormality constitutes a novel potential
clinical outcome measure in clinical trials of patients with GD3.
In summary, it is possible to study the longitudinal course of a
complex neurometabolic disorder such as Gaucher disease type 3
with objective neurological, neurophysiological and neuropsycho-
logical endpoints. Our findings indicated that the saccadic and
eye-hand coordination abnormalities are adequate representations
of the overall neurological impairment in GD3 and may be useful
as clinical outcome measures in future clinical trials.
Supporting Information
Table S1 Patient general characteristics. Bone disease
classifications: Mild, radiologic abnormalities and/or occasional mild
pain; Moderate, fractures (including avascular necrosis) and/or
chronic pain; Severe, surgery and/or disability due to pain
Abbreviations: NA, not available; ILD, interstitial lung disease; PH,
pulmonary hypertension; PF, pulmonary fibrosis; ME, myoclonic
encephalopathy, FTT, failure to thrive; BMT, bone marrow
transplant; ERT, enzyme replacement therapy, every 2 weeks dose.
(DOCX)
Table S2 Systemic disease characteristics. When there is
no entry, no data are available for that time point.
(DOCX)
Table S3 Neuropsychological testing.
(DOCX)
Table S4 Neurophysiological characteristics. Legend for
BAER score: 0-Normal absolute & normal interpeak interval 1-1-
Late absolute, normal interpeak interval 2- Late absolute,
Figure 5. Phase plane plots for saccadic velocity vs position. These are phase plane plots of saccades made by 5 subjects on a specific date to
differing target amplitudes. The origin of each saccade has been moved to zero and the velocity at each position along the saccade trajectory is
shown. Since larger amplitude saccades typically generate faster velocities, this generates a family of curves where the saccade amplitude can be
seen at the endpoint position. Here rightward curves are upward (A–F) or rightward (G–J) saccades and leftward saccades are downward (A–F) or
leftward (G–J) saccades. A and B are plots of vertical saccades for 2 different normal controls. Horizontal saccades for normal controls were also similar
to these plots and to each of the other normal controls. C and D show vertical saccades for Patient 3 at 2 different time points: D is 4 years later than
C. E and F are similar vertical saccade plots for Patient 5, who had more difficulty making saccades. F is 4 years later than E. Note that for both patients
downward saccades are slower than upward saccades. The plots in E and F also demonstrate the tendency for saccades to slow down and speed up
during the course of the saccade. Although phase plane plots of normal controls’ saccades looked similar to each other, each patient tended to have
uniquely appearing phase plots that were reproducible over time as seen in these 2 patients. G through J are plots of horizontal saccadic velocity vs
position. G and H are horizontal saccade phase plane plots for Patient 3, whose vertical saccades are plotted in C and D. Note that the horizontal
saccades are slower here and tend to have more periods of slowing than for the same patient’s vertical saccades. Again there is a 4-year time period
between G and H. I and J are horizontal saccades for Patient 11 and there is a 4-year time period between J and I. These horizontal saccades are
slower than in Patient 3 in A and B. In the later plot of both patients there is a tendency for the horizontal saccades to be slower over the 4-year
period of observation.
doi:10.1371/journal.pone.0022410.g005
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